Navigating Acute and Late-Onset Toxicities After Chimeric Antigen Receptor T-Cell Therapy: A Patient-Centered Nursing
1Karla V. Ow.
Background:
Patients with cancer undergoing advanced therapies, such as chimeric antigen receptor (CAR) T-cell therapy, experience complex treatment-related toxicities that require timely recognition and management. Nurses educate, monitor, and intervene to optimize outcomes and support quality survivorship care for patients.
Objectives:
This article highlights evidence-based interventions for managing treatment-related complications and outlines strategies to support safe, high-quality care throughout CAR T-cell treatment.
Methods:
The author conducted a literature review using PubMed®, CINAHL®, and key oncology nursing guidelines to examine relevant studies, guidance, and expert consensus statements to synthesize best practices for nursing assessment and management of immune-based therapy complications.
Findings:
Clinicians ensure safe and effective care through early toxicity recognition, standardized assessment protocols, and multidisciplinary coordination. Evidence-based interventions, as well as psychological support, contribute to improved patient outcomes. Ongoing education and professional development remain essential.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Kidney Transplant III: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease IV: Nursing Management
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
